IN VIVO MARKER OF CELL PROLIFERATION FOR PET STUDIES
IN VIVO MARKER OF CELL PROLIFERATION FOR PET STUDIES
批准号:
2871923
负责人:
Peter Stephen Conti
金额:
$55.53万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-02-21 至 2003-01-31
关键词:
DNA replication biomarker brain neoplasms breast neoplasms bromodeoxyuridine carbon cell proliferation clinical research clinical trials disease /disorder model dogs drug metabolism human subject human therapy evaluation immunocytochemistry laboratory rat neoplasm /cancer pharmacology neoplastic process nonhuman therapy evaluation outcomes research positron emission tomography prognosis prostate neoplasms radionuclides uracil nucleoside
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Advances in morphological imaging, particularly MRI and CT, have
significantly improved tumor detection, staging and measurement of therapy
response. Improvement in cancer patient management through imaging is
unlikely to continue at a similar rate unless anatomical studies are
augmented with an assessment of tumor biology and metabolism in vivo.
Progress towards this goal has been made using positron emission tomography
(PET) and an in vivo radiotracer of glucose utilization, [18F]
fluodeoxyglucose (FDG). However, FDG and other radiotracers currently used
in PET oncology studies are, at best, indirect measures of cell
proliferation. Investigators have employed traditional methodologies for
measuring DNA synthesis, such as determination of biodistribution,
biochemical radioassay, and autoradiography with [3H] or [14C] TdR, as well
as immunohistochemistry with bromodeoxyuridine (BUdR), in order to validate
the use of [11C] TdR with PET. Among the many issues surrounding
development of an in vivo method for quantitating DNA synthesis with [11C]
TdR, perhaps the most cumbersome is its rapid in vivo catabolism, which
complicates interpretation of PET kinetic data. We propose to specifically
address this issue and hypothesize that a measurement of cell proliferation
equivalent to volumetric mitotic index (MIv), i.e., the fraction of tumor
volume occupied by dividing (S-phase cells) can be achieved in vivo with
PET using a non-catabolized nucleoside anolog of thkymidine:
2'-fluoro-5-[11C]-methyl-1-beat-D-arabinofuranosyluracil (FMAU). The
efficacy of this radiotracaer for monitoring DNA synthesis will be examined
in animal tumor models and patients in comparison with MIv, as measured
with BUdR and quantitative histology. Studies using [14C] FMAU confirm the
absence of significant labeled catabolites in plasma, demonstrate that
tumors can be well visualized with PET, and indicate that uptake into tumor
and normal organs is positively correlated with MIv. We propose to test
the hypothesis that measurements of cell proliferaton paralleling BUdR
mitotic index can be obtained in vivo with PET and [11C]FMAU.
期刊论文(9)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Direct comparison of radiolabeled probes FMAU, FHBG, and FHPG as PET imaging agents for HSV1-tk expression in a human breast cancer model.
放射性标记探针 FMAU、FHBG 和 FHPG 作为 PET 显像剂直接比较人类乳腺癌模型中 HSV1-tk 的表达。
DOI:
10.1162/15353500200403160
发表时间:
2004
期刊:
Molecular imaging
影响因子:
2.8
作者:
[Alauddin,MianM, Shahinian,Atranik, Gordon,ErlindaM, Conti,PeterS]
通讯作者:
Conti,PeterS
Evaluation of 2'-deoxy-2'-flouro-5-methyl-1-beta-D-arabinofuranosyluracil as a potential gene imaging agent for HSV-tk expression in vivo.
评估 2-脱氧-2-氟-5-甲基-1-β-D-阿拉伯呋喃糖尿嘧啶作为 HSV-tk 体内表达的潜在基因成像剂。
DOI:
10.1162/15353500200202100
发表时间:
2002
期刊:
Molecular imaging
影响因子:
2.8
作者:
[Alauddin,MianM, Shahinian,Atranik, Gordon,ErlindaM, Conti,PeterS]
通讯作者:
Conti,PeterS
In vivo measurement of cell proliferation in canine brain tumor using C-11-labeled FMAU and PET.
使用 C-11 标记的 FMAU 和 PET 体内测量犬脑肿瘤中的细胞增殖。
DOI:
10.1016/j.nucmedbio.2007.09.003
发表时间:
2008
期刊:
Nuclear medicine and biology
影响因子:
3.1
作者:
[Conti,PeterS, Bading,JamesR, Mouton,PeterP, Links,JonathanM, Alauddin,MianM, Fissekis,JohnD, Ravert,HaydenT, Hilton,John, Wong,DeanF, Anderson,JamesH]
通讯作者:
Anderson,JamesH
Pharmacokinetics of the thymidine analog 2'-fluoro-5-[(14)C]-methyl-1-beta-D-arabinofuranosyluracil ([(14)C]FMAU) in rat prostate tumor cells.
胸苷类似物 2-氟-5-[(14)C]-甲基-1-β-D-阿拉伯呋喃糖尿嘧啶 ([(14)C]FMAU) 在大鼠前列腺肿瘤细胞中的药代动力学。
DOI:
10.1016/s0969-8051(00)00100-1
发表时间:
2000
期刊:
Nuclear medicine and biology
影响因子:
3.1
作者:
[Bading,JR, Shahinian,AH, Bathija,P, Conti,PS]
通讯作者:
Conti,PS
DOI:
--
发表时间:
2004
期刊:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
影响因子:
--
作者:
[M. Alauddin;Antranic Shahinian;R. Park;M. Tohme;J. Fissekis;P. Conti]
通讯作者:
M. Alauddin;Antranic Shahinian;R. Park;M. Tohme;J. Fissekis;P. Conti
Phase Contrast Tomographic X-Ray Microscope System
-
批准号:8734930
-
项目类别:
-
资助金额:$111.13万
-
财政年份:2015
-
负责人:Peter Stephen Conti
-
依托单位:
Small Animal Photoacoustic Imaging Unit: Integrating Optical Imaging with High Fr
-
批准号:8640794
-
项目类别:
-
资助金额:$59.9万
-
财政年份:2014
-
负责人:Peter Stephen Conti
-
依托单位:
The Tetrazine Ligation for Efficient 18F Labeling and Pretargeted Imaging/Radiotherapy of Cancer
-
批准号:8900694
-
项目类别:
-
资助金额:$34.66万
-
财政年份:2013
-
负责人:Peter Stephen Conti
-
依托单位:
Cyclotron for Molecular Imaging Program at USC
-
批准号:7841076
-
项目类别:
-
资助金额:$308.2万
-
财政年份:2011
-
负责人:Peter Stephen Conti
-
依托单位:
EphB4 as Novel Target for Breast Cancer Imaging
-
批准号:8114963
-
项目类别:
-
资助金额:$24.3万
-
财政年份:2011
-
负责人:Peter Stephen Conti
-
依托单位:
EphB4 as Novel Target for Breast Cancer Imaging
-
批准号:8245791
-
项目类别:
-
资助金额:$20.25万
-
财政年份:2011
-
负责人:Peter Stephen Conti
-
依托单位:
Ultra-High Resolution CT Specimen Scanner for In Vitro Applications
-
批准号:7795629
-
项目类别:
-
资助金额:$49.16万
-
财政年份:2010
-
负责人:Peter Stephen Conti
-
依托单位:
Digital X-Ray Device for Molecular Imaging Center
-
批准号:7795619
-
项目类别:
-
资助金额:$13.48万
-
财政年份:2010
-
负责人:Peter Stephen Conti
-
依托单位:
High Resolution Ultrasound Resource for Molecular Imaging Center
-
批准号:7215090
-
项目类别:
-
资助金额:$36.2万
-
财政年份:2007
-
负责人:Peter Stephen Conti
-
依托单位:
IMAGING SYSTEM: MAGNESIUM DEFICIENCY: BONE & MINERAL METABOLISM IN RAT
-
批准号:6973482
-
项目类别:
-
资助金额:$12.61万
-
财政年份:2004
-
负责人:Peter Stephen Conti
-
依托单位:
Micro Computerized Tomography Imaging System
-
批准号:6731469
-
项目类别:
-
资助金额:$37.83万
-
财政年份:2004
-
负责人:Peter Stephen Conti
-
依托单位:
IMAGING SYSTEM: BONE & OSTEOPOROSIS, MOUSE MODEL
-
批准号:6973481
-
项目类别:
-
资助金额:$12.61万
-
财政年份:2004
-
负责人:Peter Stephen Conti
-
依托单位:
IMAGING SYSTEM: CANCERS: PROSTATE, COLON
-
批准号:6973480
-
项目类别:
-
资助金额:$12.61万
-
财政年份:2004
-
负责人:Peter Stephen Conti
-
依托单位:
Development of a Cellular and Molecular-Based Cancer Im*
-
批准号:6514556
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2001
-
负责人:Peter Stephen Conti
-
依托单位:
Development of a Cellular and Molecular-Based Cancer Im*
-
批准号:6344464
-
项目类别:
-
资助金额:$39.2万
-
财政年份:2001
-
负责人:Peter Stephen Conti
-
依托单位:
SMALL ANIMAL PET SCANNER FOR CANCER APPLICATIONS
-
批准号:6288088
-
项目类别:
-
资助金额:$49.55万
-
财政年份:2001
-
负责人:Peter Stephen Conti
-
依托单位:
Development of a Cellular and Molecular-Based Cancer Im*
-
批准号:6658927
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2001
-
负责人:Peter Stephen Conti
-
依托单位:
DUAL HOT CELL SYSTEM AND AUXILLARY EQUIPMENT
-
批准号:2503076
-
项目类别:
-
资助金额:$34.31万
-
财政年份:1998
-
负责人:Peter Stephen Conti
-
依托单位:
IN VIVO MARKER OF CELL PROLIFERATION FOR PET STUDIES
-
批准号:2654249
-
项目类别:
-
资助金额:$51.62万
-
财政年份:1997
-
负责人:Peter Stephen Conti
-
依托单位:
IN VIVO MARKER OF CELL PROLIFERATION FOR PET STUDIES
-
批准号:2010953
-
项目类别:
-
资助金额:$52.03万
-
财政年份:1997
-
负责人:Peter Stephen Conti
-
依托单位:
国内基金
海外基金
基于DNA甲基化交互网络的癌症hallmark挖掘及其在癌症转移biomarker筛选中的应用
-
批准号:61602201
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2016
-
负责人:周雄辉
-
依托单位:
血清miRNAs成为一种新的biomarker在PD诊断中的价值和LRRK2基因调控的机制研究
-
批准号:81170309
-
项目类别:面上项目
-
资助金额:50.0万元
-
批准年份:2011
-
负责人:颜桥
-
依托单位:
非小细胞肺癌Biomarker的Imaging MS研究新方法
-
批准号:30672394
-
项目类别:面上项目
-
资助金额:30.0万元
-
批准年份:2006
-
负责人:陆豪杰
-
依托单位: